Submit Feedback
Recent searches
    Trending searches
    Bristol-Myers Squibb Company
    +
    Revenue breakdown by Products & Services
    Revenue breakdown by Geography

    Bristol-Myers Squibb Company's Revenue by Segment

    In fiscal year , Bristol-Myers Squibb Company's revenue by segment (products & services) are as follows:


    Learn more about Bristol-Myers Squibb Company’s Revenue by Geography

    Check out competitors to Bristol-Myers Squibb Company in a side-by-side comparison.

    Explore additional financial metrics for Bristol-Myers Squibb Company.

    Continue reading...

    The above chart shows Bristol-Myers Squibb Company's revenue percentage share by segment (products and services).

    In fiscal year 2022, Bristol-Myers Squibb Company's revenue by segment is as follows:

    • Abecma generated $388.00M in revenue, representing 0.87% of its total revenue.
    • Abraxane generated $811.00M in revenue, representing 1.83% of its total revenue.
    • Breyanzi generated $182.00M in revenue, representing 0.41% of its total revenue.
    • Camzyos generated $24.00M in revenue, representing 0.05% of its total revenue.
    • Eliquis generated $11.79B in revenue, representing 26.55% of its total revenue.
    • Empliciti generated $296.00M in revenue, representing 0.67% of its total revenue.
    • Inrebic generated $85.00M in revenue, representing 0.19% of its total revenue.
    • Onureg generated $124.00M in revenue, representing 0.28% of its total revenue.
    • Opdivo generated $8.25B in revenue, representing 18.57% of its total revenue.
    • Opdualag generated $252.00M in revenue, representing 0.57% of its total revenue.
    • Orencia generated $3.46B in revenue, representing 7.8% of its total revenue.
    • Pomalyst/Imnovid generated $3.50B in revenue, representing 7.87% of its total revenue.
    • Reblozyl generated $717.00M in revenue, representing 1.61% of its total revenue.
    • Revlimid generated $9.98B in revenue, representing 22.47% of its total revenue.
    • Sotyktu generated $8.00M in revenue, representing 0.02% of its total revenue.
    • Sprycel generated $2.17B in revenue, representing 4.88% of its total revenue.
    • Yervoy generated $2.13B in revenue, representing 4.8% of its total revenue.
    • Zeposia generated $250.00M in revenue, representing 0.56% of its total revenue.

    The biggest segment for Bristol-Myers Squibb Company is the Eliquis, which represents 26.55% of its total revenue.
    The smallest segment for Bristol-Myers Squibb Company is the Sotyktu, which represents 0.02% of its total revenue.
    Continue reading...

    Summary Table

    Products & Services (Percent Share) 2022 2024
    Opdualag 0.57% -
    Zeposia 0.56% -
    Yervoy 4.8% -
    Sprycel 4.88% -
    Sotyktu 0.02% -
    Revlimid 22.47% -
    Reblozyl 1.61% -
    Pomalyst/Imnovid 7.87% -
    Orencia 7.8% -
    Abecma 0.87% -
    Opdivo 18.57% -
    Onureg 0.28% -
    Inrebic 0.19% -
    Empliciti 0.67% -
    Eliquis 26.55% -
    Camzyos 0.05% -
    Breyanzi 0.41% -
    Abraxane 1.83% -
    Total Revenue 100% 100%

    The above chart shows growth drivers and a year-over-year comparison of different segments' revenue.

    Continue reading...

    Summary Table

    Products & Services 2022
    Value Change
    		2023
    Value Change
    		2024
    Value Change
    Abecma $388.00M - - - - -
    Abraxane $811.00M - - - - -
    Breyanzi $182.00M - - - - -
    Camzyos $24.00M - - - - -
    Eliquis $11.79B - - - - -
    Empliciti $296.00M - - - - -
    Inrebic $85.00M - - - - -
    Onureg $124.00M - - - - -
    Opdivo $8.25B - - - - -
    Opdualag $252.00M - - - - -
    Orencia $3.46B - - - - -
    Pomalyst/Imnovid $3.50B - - - - -
    Reblozyl $717.00M - - - - -
    Revlimid $9.98B - - - - -
    Sotyktu $8.00M - - - - -
    Sprycel $2.17B - - - - -
    Yervoy $2.13B - - - - -
    Zeposia $250.00M - - - - -
    Total Revenue $44.41B - -
    100.00%
    		- -

    Related company

    Related